|
 The move reflects a commitment to fundamental research by the
British company, even as its shifts emphasis to greater reliance on
non-pharmaceutical businesses such as consumer healthcare and
vaccines.
Cells are often referred to as the building blocks of life, but they
can be thought of in computer terms, with their own internal
operating systems. Scientists have only limited understanding of
this area, but by unpicking the puzzle they could gain invaluable
help in determining where to start when developing drugs.
The non-profit Altius Institute for Biomedical Sciences in Seattle
will be led by John Stamatoyannopoulos, of the University of
Washington School of Medicine, with GSK providing more than $95
million in cash and other resources.
GSK has retained first rights to the institute’s inventions and will
be able to invest in commercialization of its discoveries via
spin-out companies.
[to top of second column] |
The institute is expected to be operational before the end of the
year.
(Reporting by Ben Hirschler; Editing by David Goodman)
[© 2015 Thomson Reuters. All rights
reserved.]
Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
